These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 33724511)

  • 21. Serum ferritin levels predict histological severity in patients with nonalcoholic fatty liver disease in India.
    Parikh P; Patel J; Ingle M; Sawant P
    Indian J Gastroenterol; 2015 May; 34(3):200-8. PubMed ID: 26108652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. qFIBS: An Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis.
    Liu F; Goh GB; Tiniakos D; Wee A; Leow WQ; Zhao JM; Rao HY; Wang XX; Wang Q; Wan WK; Lim KH; Romero-Gomez M; Petta S; Bugianesi E; Tan CK; Harrison SA; Anstee QM; Chang PJ; Wei L
    Hepatology; 2020 Jun; 71(6):1953-1966. PubMed ID: 31600834
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.
    Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M
    J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.
    Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Hultcrantz R; Kechagias S
    J Hepatol; 2017 Dec; 67(6):1265-1273. PubMed ID: 28803953
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The nonalcoholic steatohepatitis extended hepatocyte ballooning score: histologic classification and clinical significance.
    Gill RM; Allende D; Belt PH; Behling CA; Cummings OW; Guy CD; Carpenter D; Neuschwander-Tetri BA; Sanyal AJ; Tonascia J; Van Natta ML; Wilson LA; Yamada G; Yeh M; Kleiner DE;
    Hepatol Commun; 2023 Feb; 7(2):e0033. PubMed ID: 36724127
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-Throughput, Machine Learning-Based Quantification of Steatosis, Inflammation, Ballooning, and Fibrosis in Biopsies From Patients With Nonalcoholic Fatty Liver Disease.
    Forlano R; Mullish BH; Giannakeas N; Maurice JB; Angkathunyakul N; Lloyd J; Tzallas AT; Tsipouras M; Yee M; Thursz MR; Goldin RD; Manousou P
    Clin Gastroenterol Hepatol; 2020 Aug; 18(9):2081-2090.e9. PubMed ID: 31887451
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Testosterone is Associated With Nonalcoholic Steatohepatitis and Fibrosis in Premenopausal Women With NAFLD.
    Sarkar MA; Suzuki A; Abdelmalek MF; Yates KP; Wilson LA; Bass NM; Gill R; Cedars M; Terrault N;
    Clin Gastroenterol Hepatol; 2021 Jun; 19(6):1267-1274.e1. PubMed ID: 33010412
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vitamin D is Not Associated With Severity in NAFLD: Results of a Paired Clinical and Gene Expression Profile Analysis.
    Patel YA; Henao R; Moylan CA; Guy CD; Piercy DL; Diehl AM; Abdelmalek MF
    Am J Gastroenterol; 2016 Nov; 111(11):1591-1598. PubMed ID: 27644736
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Portal lymphadenopathy predicts non-alcoholic steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease.
    Daher S; Lev Cohen N; Massarwa M; Mahamid M; Nasser M; Hazou W; Oren R; Safadi R; Khoury T
    PLoS One; 2018; 13(11):e0207479. PubMed ID: 30500848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatic sonic hedgehog protein expression measured by computer assisted morphometry significantly correlates with features of non-alcoholic steatohepatitis.
    Estep M; Mehta R; Bratthauer G; Alaparthi L; Monge F; Ali S; Abdelatif D; Younoszai Z; Stepanova M; Goodman ZD; Younossi ZM
    BMC Gastroenterol; 2019 Feb; 19(1):27. PubMed ID: 30744560
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis.
    Pelusi S; Cespiati A; Rametta R; Pennisi G; Mannisto V; Rosso C; Baselli G; Dongiovanni P; Fracanzani AL; Badiali S; Maggioni M; Craxi A; Fargion S; Prati D; Nobili V; Bugianesi E; Romeo S; Pihlajamaki J; Petta S; Valenti L
    Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2310-2319.e6. PubMed ID: 30708111
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatic FATP5 expression is associated with histological progression and loss of hepatic fat in NAFLD patients.
    Enooku K; Tsutsumi T; Kondo M; Fujiwara N; Sasako T; Shibahara J; Kado A; Okushin K; Fujinaga H; Nakagomi R; Minami T; Sato M; Uchino K; Nakagawa H; Kondo Y; Asaoka Y; Tateishi R; Ueki K; Ikeda H; Yoshida H; Moriya K; Yotsuyanagi H; Kadowaki T; Koike K
    J Gastroenterol; 2020 Feb; 55(2):227-243. PubMed ID: 31602526
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors.
    Leite NC; Villela-Nogueira CA; Pannain VL; Bottino AC; Rezende GF; Cardoso CR; Salles GF
    Liver Int; 2011 May; 31(5):700-6. PubMed ID: 21457442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathology of non-alcoholic fatty liver disease.
    Bedossa P
    Liver Int; 2017 Jan; 37 Suppl 1():85-89. PubMed ID: 28052629
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease.
    Kowdley KV; Belt P; Wilson LA; Yeh MM; Neuschwander-Tetri BA; Chalasani N; Sanyal AJ; Nelson JE;
    Hepatology; 2012 Jan; 55(1):77-85. PubMed ID: 21953442
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD.
    Takahashi H; Kessoku T; Kawanaka M; Nonaka M; Hyogo H; Fujii H; Nakajima T; Imajo K; Tanaka K; Kubotsu Y; Isoda H; Oeda S; Kurai O; Yoneda M; Ono M; Kitajima Y; Tajiri R; Takamori A; Kawaguchi A; Aishima S; Kage M; Nakajima A; Eguchi Y; Anzai K
    Hepatol Commun; 2022 Jan; 6(1):120-132. PubMed ID: 34558835
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association between dietary total antioxidant capacity and hepatocellular ballooning in nonalcoholic steatohepatitis: a cross-sectional study.
    de Oliveira DG; de Faria Ghetti F; Moreira APB; Hermsdorff HHM; de Oliveira JM; de Castro Ferreira LEVV
    Eur J Nutr; 2019 Sep; 58(6):2263-2270. PubMed ID: 30019089
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current status, problems, and perspectives of non-alcoholic fatty liver disease research.
    Tanaka N; Kimura T; Fujimori N; Nagaya T; Komatsu M; Tanaka E
    World J Gastroenterol; 2019 Jan; 25(2):163-177. PubMed ID: 30670907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein in non-alcoholic fatty liver disease.
    Lai LL; Chan WK; Sthaneshwar P; Nik Mustapha NR; Goh KL; Mahadeva S
    PLoS One; 2017; 12(4):e0174982. PubMed ID: 28369100
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
    Taylor RS; Taylor RJ; Bayliss S; Hagström H; Nasr P; Schattenberg JM; Ishigami M; Toyoda H; Wai-Sun Wong V; Peleg N; Shlomai A; Sebastiani G; Seko Y; Bhala N; Younossi ZM; Anstee QM; McPherson S; Newsome PN
    Gastroenterology; 2020 May; 158(6):1611-1625.e12. PubMed ID: 32027911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.